Search
Vespula pensylvanica venom protein
go.drugbank.com/drugs/DB11031ApprovedVespula pensylvanica venom protein is an extract of Vespula pensylvanica venom. Vespula pensylvanica venom protein is used in allergenic testing.
Tonapofylline
go.drugbank.com/drugs/DB12569InvestigationalTonapofylline has been used in trials studying the treatment of Heart Failure, Renal Insufficiency, and Congestive Heart Failure.
SUVN-502
go.drugbank.com/drugs/DB06140InvestigationalSUVN-502 is a novel, potent, safe, highly selective and orally active antagonist at a central nervous system serotonin receptor site 5-HT6 intended for treatment of cognitive disorders such as Alzheimer … ’s and Schizophrenia, an unmet medical need.
Davunetide
go.drugbank.com/drugs/DB12613InvestigationalDavunetide is derived from a naturally occurring neuroprotective brain protein known as activity dependent neuroprotective protein. … Davunetide is the first drug to improve memory performance by impacting the mechanisms that lead to physical damage in the brain caused by neurofibrillary tangles, one of the two established pathological
Segatroxaban
go.drugbank.com/drugs/DB21678ExperimentalSegatroxaban is a small molecule drug. The usage of the INN stem '-xaban' in the name indicates that Segatroxaban is a blood coagulation factor XA inhibitor, antithrombotic. … Segatroxaban has a monoisotopic molecular weight of 567.14 Da.
Oftasceine
go.drugbank.com/drugs/DB11184ApprovedOftasceine is also referred to as Fluorexon. It is used in ophthalmic solutions as a staining agent when fitting soft and hard lenses. It is a fluorescent dye or luminescent agent.
Mucor circinelloides f. lusitanicus
go.drugbank.com/drugs/DB15525ApprovedMucor circinelloides f. lusitanicus allergenic extract is used in allergenic testing.
Coffea arabica seed, roasted
go.drugbank.com/drugs/DB15603ApprovedCoffea arabica seed, roasted allergenic extract is used in allergenic testing.
NRP369
go.drugbank.com/drugs/DB06384ExperimentalNRP369 is an oxycodone derivative under investigation for the treatment of pain (moderate to moderately severe). NRP369 was developed by New River Pharmaceuticals as a backup therapeutic to [NRP290].